Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Stupp

Showing results (161-170 of 314) with videos related to

Pageof 32
Sort By:
Drug Discovery Today|June 25, 2013
Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentaryMonika A Jarzabek, Kieron J Sweeney, Rhys L Evans, et al.
Neuro-Oncology|October 20, 2024
Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?Ruochen Du, Jianzhong Zhang, Rimas V Lukas, et al.
Scientific Reports|October 21, 2015
Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparisonTim De Meyer, Pierre Bady, Geert Trooskens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2018
<i>MGMT</i> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical TrialsMonika E Hegi, Els Genbrugge, Thierry Gorlia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2014
Reply to M.C. ChamberlainMark R Gilbert, James Dignam, Stephanie Pugh, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 4, 2014
Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myelomaPanagiotis Samaras, Sarah Pfrommer, Burkhardt Seifert, et al.
Neuro-Oncology|June 1, 2010
Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapyPatrick Beauchesne, Valerie Bernier, Charlotte Carnin, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2010
An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patientsMartin J B Taphoorn, Lily Claassens, Neil K Aaronson, et al.
Brain Pathology (Zurich, Switzerland)|April 11, 2008
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarkerMatthias Preusser, Robert Charles Janzer, Jörg Felsberg, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2012
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumoursSilke Gillessen, Ulrike S Gnad-Vogt, Elisa Gallerani, et al.
Pageof 32

Showing results (161-170 of 314) with videos related to

Sort By:
Pageof 32
Drug Discovery Today|June 25, 2013
Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentaryMonika A Jarzabek, Kieron J Sweeney, Rhys L Evans, et al.
Neuro-Oncology|October 20, 2024
Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?Ruochen Du, Jianzhong Zhang, Rimas V Lukas, et al.
Scientific Reports|October 21, 2015
Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparisonTim De Meyer, Pierre Bady, Geert Trooskens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2018
<i>MGMT</i> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical TrialsMonika E Hegi, Els Genbrugge, Thierry Gorlia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2014
Reply to M.C. ChamberlainMark R Gilbert, James Dignam, Stephanie Pugh, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 4, 2014
Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myelomaPanagiotis Samaras, Sarah Pfrommer, Burkhardt Seifert, et al.
Neuro-Oncology|June 1, 2010
Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapyPatrick Beauchesne, Valerie Bernier, Charlotte Carnin, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2010
An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patientsMartin J B Taphoorn, Lily Claassens, Neil K Aaronson, et al.
Brain Pathology (Zurich, Switzerland)|April 11, 2008
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarkerMatthias Preusser, Robert Charles Janzer, Jörg Felsberg, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2012
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumoursSilke Gillessen, Ulrike S Gnad-Vogt, Elisa Gallerani, et al.
Pageof 32